Drugs / WT1-sensitized T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00620633 | Feb 2008 → Feb 2021 | leukemia, myelodysplastic syndrome | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1-sensitized T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00620633 ↗ |
| Action | Deplete | “kill the leukemia cells” NCT00620633 ↗ |
| Modality | Cell therapy | “They are called WT1 sensitized T cells.” NCT00620633 ↗ |
| Route | Intravenous | “bolus intravenous infusion” NCT00620633 ↗ |